<DOC>
	<DOC>NCT02848833</DOC>
	<brief_summary>To monitor the safety profile and effectiveness of Empagliflozin in Korea patients with type 2 diabetes mellitus in a routine clinical practice setting</brief_summary>
	<brief_title>JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criteria: 1. Patients who have been started on JARDIANCE® in accordance with the approved label in Korea 2. Age = 19 years at enrolment 3. Patients who have signed on the data release consent form Exclusion criteria: 1. Known hypersensitivity to empagliflozin or any of its excipients 2. Patients with type 1 diabetes or for the treatment of diabetic ketoacidosis 3. Patients with persistent estimated Glomerular Filtration Rate &lt;60 mL/min/1.73 m2,end stage renal disease or on dialysis 4. Patients with rare hereditary conditions of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption 5. Patients for whom empagliflozin is contraindicated according local label of JARDIANCE®</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>110 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>